Illumina, Inc. (ILMN)

NASDAQ: ILMN · IEX Real-Time Price · USD
140.50
+0.67 (0.48%)
At close: Mar 1, 2024, 4:00 PM
139.35
-1.15 (-0.82%)
After-hours: Mar 1, 2024, 7:59 PM EST
0.48%
Market Cap 22.33B
Revenue (ttm) 4.50B
Net Income (ttm) -1.16B
Shares Out 158.90M
EPS (ttm) -7.34
PE Ratio n/a
Forward PE 163.83
Dividend n/a
Ex-Dividend Date n/a
Volume 1,898,734
Open 139.20
Previous Close 139.83
Day's Range 135.47 - 142.70
52-Week Range 89.00 - 238.55
Beta 1.22
Analysts Buy
Price Target 173.20 (+23.27%)
Earnings Date Apr 23, 2024

About ILMN

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio... [Read more]

Sector Healthcare
IPO Date Jul 28, 2000
Employees 13,360
Stock Exchange NASDAQ
Ticker Symbol ILMN
Full Company Profile

Financial Performance

In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $173.2, which is an increase of 23.27% from the latest price.

Price Target
$173.2
(23.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Illumina forecasts flat 2024 sales as sluggish demand drags on

Illumina on Thursday forecast its annual core business revenue to be nearly flat compared to fiscal year 2023 as subdued demand for its genetic testing tools and diagnostics products extends into this...

24 days ago - Reuters

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency ...

24 days ago - PRNewsWire

Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO , Jan. 15, 2024 /PRNewswire/ -- Concentr...

Other symbols: DNA
6 weeks ago - PRNewsWire

Illumina Ventures Labs Launches in the US and the UK to Enable More Rapid Value-Creation for Start-Ups Advancing Human Health

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #biotech--Illumina® Ventures Labs, an early-stage company creation and investment engine, is now operational and finalizing agreements with several startups.

7 weeks ago - Business Wire

Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023

SAN DIEGO , Jan. 9, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023...

7 weeks ago - PRNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Illumina, Inc.(ILMN) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN) of a class action securities lawsuit. CLASS DEFINITION: ...

7 weeks ago - PRNewsWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investo...

7 weeks ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Illumina, Inc. of Class Action Lawsuit and Upcoming Deadline - ILMN

NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Illumina, Inc ("Illumina" or the "Company") (NASDAQ: ILMN).   The class action, filed...

2 months ago - PRNewsWire

Illumina expands collaboration with Janssen to advance molecular residual disease cancer test

SAN DIEGO , Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research ...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2024 - (NASDAQ: ILMN)

NEW YORK , Jan. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Illumina, Inc.. Shareholders who purchased shares of ILMN during the class period listed are e...

2 months ago - PRNewsWire

Jim Cramer looks at the worst Nasdaq performers of 2023

'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.

Other symbols: AEPEXCMRNAPYPLWBAXEL
2 months ago - CNBC Television

Illumina's story is too messy and uncertain right now, says Jim Cramer

'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.

2 months ago - CNBC Television

Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024

SAN DIEGO , Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, F...

2 months ago - PRNewsWire

ILLUMINA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Illumina To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in Illumina securities between September 21, 2020 and November 9, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...

2 months ago - PRNewsWire

The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk

AGD delivered ~86,000 whole genomes in 2023, including a unique diverse ancestry cohort Expanded pharma engagement enhances AGD's ability to develop multiomic datasets SAN DIEGO , Jan. 4, 2024 /PRNews...

2 months ago - PRNewsWire

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action - ILMN

NEW YORK , Jan. 2, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2...

2 months ago - PRNewsWire

Here are the 20 worst-performing stocks among the S&P 500 in 2023

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Other symbols: AESALBBMYCAGDGDVNEL
2 months ago - Market Watch

ILMN Investors Have Opportunity to Lead Illumina, Inc. Securities Fraud Lawsuit

LOS ANGELES , Dec. 28, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...

2 months ago - PRNewsWire

ILLUMINA INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Illumina To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in Illumina securities between September 21, 2020 and November 9, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...

2 months ago - PRNewsWire

Important January 9, 2024 Deadline Reminder for Illumina, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. (ILMN) Investors of Securities Fraud Class Action Lawsuit

RADNOR, Pa. , Dec. 26, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United Sta...

2 months ago - PRNewsWire

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Illumina, Inc.

NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit for violations of the federal securities laws in t...

2 months ago - Business Wire

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42nd Annual J.P. Morgan Healthcare Co...

2 months ago - PRNewsWire

Activist Icahn prepares a second board challenge at Illumina -letter

Activist investor Carl Icahn said on Monday that he plans to oust directors at Illumina, laying the groundwork for a second board challenge at the gene-sequencing company months after shareholders ele...

2 months ago - Reuters

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Illumina, Inc. - ILMN

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN). Such investors are advised to cont...

2 months ago - PRNewsWire

Illumina Gives Up Fight With Regulators, Will Divest GRAIL

The saga over DNA sequencing firm Illumina Inc.'s (ILMN) controversial purchase of cancer diagnostic test maker GRAIL appears to be over.

2 months ago - Investopedia